Takeda Returns Exclusive Rights for Gastrointestinal Assets to BioSurfaces
Ashland, MA; September 16, 2024 – Takeda Pharmaceutical Company Limited has returned to BioSurfaces the exclusive rights in BioSurfaces’...
Takeda Returns Exclusive Rights for Gastrointestinal Assets to BioSurfaces
Mark Guitarini Joins BioSurfaces Business Advisory Board
BioSurfaces Nominated for Manufacturing Award
BioSurfaces Unveils Next-Gen 3D Bio-Spun™ Scaffolds in the AKITA Plate!
How Can BioSurfaces Help You? (FDA Modernization Act 2.0)
BioSurfaces Receives $1.72 Million Small Business Innovation Research (SBIR) Direct Phase II Grant
Jean Angus Joins BioSurfaces Business Advisory Board
BioSurfaces Receives Strategic Investment from Saint-Gobain
Ben Dunn and John Brooks III Join BioSurfaces Business Advisory Board
BioSurfaces Extends Research and Development with Takeda